CN112955445A - 化合物A的晶型α及其制备方法和含有该晶型的药物组合物 - Google Patents

化合物A的晶型α及其制备方法和含有该晶型的药物组合物 Download PDF

Info

Publication number
CN112955445A
CN112955445A CN201980064845.8A CN201980064845A CN112955445A CN 112955445 A CN112955445 A CN 112955445A CN 201980064845 A CN201980064845 A CN 201980064845A CN 112955445 A CN112955445 A CN 112955445A
Authority
CN
China
Prior art keywords
degrees
compound
crystal form
alpha
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980064845.8A
Other languages
English (en)
Other versions
CN112955445B (zh
Inventor
许文杰
孙晶超
于涛
毛庆华
张盛彬
李宁
吴成德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Salubris Pharmaceuticals Co Ltd
Original Assignee
Shenzhen Salubris Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Salubris Pharmaceuticals Co Ltd filed Critical Shenzhen Salubris Pharmaceuticals Co Ltd
Publication of CN112955445A publication Critical patent/CN112955445A/zh
Application granted granted Critical
Publication of CN112955445B publication Critical patent/CN112955445B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4462—Non condensed piperidines, e.g. piperocaine only substituted in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

公开了一种PCSK9抑制剂化合物A的晶型α及其制备方法，以及含有该晶型的药物组合物。

Description

PCT国内申请，说明书已公开。

Claims (10)

  1. PCT国内申请，权利要求书已公开。
CN201980064845.8A 2018-10-18 2019-09-23 化合物A的晶型α及其制备方法和含有该晶型的药物组合物 Active CN112955445B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201811212504 2018-10-18
CN2018112125044 2018-10-18
PCT/CN2019/107211 WO2020078170A1 (zh) 2018-10-18 2019-09-23 化合物A的晶型α及其制备方法和含有该晶型的药物组合物

Publications (2)

Publication Number Publication Date
CN112955445A true CN112955445A (zh) 2021-06-11
CN112955445B CN112955445B (zh) 2022-05-17

Family

ID=70283529

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980064845.8A Active CN112955445B (zh) 2018-10-18 2019-09-23 化合物A的晶型α及其制备方法和含有该晶型的药物组合物

Country Status (2)

Country Link
CN (1) CN112955445B (zh)
WO (1) WO2020078170A1 (zh)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105143203A (zh) * 2013-04-17 2015-12-09 辉瑞大药厂 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
WO2018192493A1 (zh) * 2017-04-21 2018-10-25 深圳信立泰药业股份有限公司 作为pcsk9抑制剂的哌啶类化合物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105143203A (zh) * 2013-04-17 2015-12-09 辉瑞大药厂 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
WO2018192493A1 (zh) * 2017-04-21 2018-10-25 深圳信立泰药业股份有限公司 作为pcsk9抑制剂的哌啶类化合物

Also Published As

Publication number Publication date
CN112955445B (zh) 2022-05-17
WO2020078170A1 (zh) 2020-04-23

Similar Documents

Publication Publication Date Title
JP7444957B2 (ja) ２－ヒドロキシ－６－（（２－（１－イソプロピル－１ｈ－ピラゾール－５－イル）ピリジン－３－イル）メトキシ）ベンズアルデヒドの遊離塩基の結晶多形
JP2022190155A (ja) 高純度医薬品等級タシメルテオン
EP3122753A2 (en) Ibrutinib solid forms and production process therefor
CN103221411B (zh) (R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺盐酸盐单水合物的晶型
CN104781272A (zh) 奥贝胆酸的制备、用途和固体形式
JP2009280604A (ja) Ｎ−（４−トリフルオロメチルフェニル）−５−メチルイソオキサゾール−４−カルボキサミドの結晶形態の製造方法
CN104080777B (zh) 用作mogat-2抑制剂的吗啉基衍生物
CN1852713A (zh) 孟鲁司特钠的多晶型
CN101691372B (zh) 枸橼酸爱地那非晶型c及其制备方法和用途
CN112955445B (zh) 化合物A的晶型α及其制备方法和含有该晶型的药物组合物
KR20230038229A (ko) 우파다시티닙의 결정형, 이의 제조 방법 및 이의 용도
CN114644642B (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
WO2018214877A1 (zh) 一种地佐辛晶型及其制备方法
KR101737883B1 (ko) 미네랄코르티코이드 수용체 길항제로서 사용된 화합물의 결정형 및 이의 제조방법
CN104447683A (zh) 一种稳定的比拉斯汀化合物
TWI378929B (en) Crystalline 1h-imidazo[4,5-b]pyridin-5-amine, 7-[5-[(cyclohexylmethylamino)-methyl]-1h-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its pharmaceutical uses
CN107663173A (zh) 恩杂鲁胺及其制备方法和用途
JP2023523453A (ja) Ｍ受容体拮抗剤の結晶体、調製方法及びその応用
EP2767544A1 (en) Amorphous substance of 17 -acetoxy-11 -(4-n,n-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione and preparation method thereof
CN115397426B (zh) 伊布替尼葡萄糖酸内酯共晶体及其制备方法
CN115322150B (zh) 氘代右美沙芬氢溴酸盐的固体及其制备方法和医药用途
WO2023131017A1 (zh) 一种稠环衍生物的晶型、其制备方法及其应用
WO2023143321A1 (zh) 他伐帕敦的晶型及其制备方法和用途
CN107663198A (zh) 奥美沙坦酯及其制备方法和用途
JP2008540449A (ja) （２ｅ，４ｓ）−４−［（ｎ−｛［（２ｒ）−１−イソプロピルピペリジン−２−イル］−カルボニル｝−３−メチル−ｌ−バリル）（メチル）アミノ］−２，５−ジメチルヘキサ−２−エン酸の非溶媒和およびホストゲスト溶媒和結晶フォーム、およびそれらの医薬的使用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP02 Change in the address of a patent holder
CP02 Change in the address of a patent holder

Address after: Area A, 4th Floor, Digital Peninsula, No. 2, Hongliu Road, Fubao Community, Fubao Street, Futian District, Shenzhen, Guangdong, 518017

Patentee after: SHENZHEN SALUBRIS PHARMACEUTICALS Co.,Ltd.

Address before: 518040 37th floor, chegongmiao Lvjing Plaza, 6009 Shennan Avenue, Futian District, Shenzhen City, Guangdong Province

Patentee before: SHENZHEN SALUBRIS PHARMACEUTICALS Co.,Ltd.